Why Amylyx Pharmaceuticals Stock Skyrocketed Today
Key Points
Amylyx is developing a GLP-1 treatment for people with chronic low blood sugar.
The experimental therapy displayed a favorable safety profile in a clinical study.
- 10 stocks we like better than Amylyx Pharmaceuticals ›
Shares of Amylyx Pharmaceuticals (NASDAQ: AMLX) surged on Tuesday after the biotechnology company announced positive clinical trial results for its investigational glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
An unmet medical need
Roughly 8% of the 160,000 people in the U.S. who have had the two most common types of bariatric (weight loss) surgeries -- sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) -- suffer from chronic hypoglycemia, or low blood sugar.
Post-bariatric hypoglycemia (PBH) can cause serious medical issues, including cognitive dysfunction, physical impairment, loss of consciousness, and seizures. Yet there are currently no FDA-approved therapies for PBH.
An exaggerated GLP-1 response after eating, which causes a rapid drop in blood glucose, is believed to be a primary driver of PBH.
Encouraging results
Avexitide met its primary endpoint in a Phase 3 study in participants with PBH following RYGB surgery, demonstrating a 55% reduction in severe hypoglycemic events compared to placebo.
Importantly, avexitide was also generally well-tolerated, with no serious adverse events related to treatment.
"Today's results are a major milestone that demonstrate avexitide's potential to address a critical treatment gap for the PBH community and represent a meaningful step forward for people living with this condition," Amylyx chief medical officer Camille Bedrosian said.
Amylyx intends to file a New Drug Application (NDA) with the FDA by the end of the year.
Should you buy stock in Amylyx Pharmaceuticals right now?
Before you buy stock in Amylyx Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amylyx Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,040!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of August 18, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
